title: Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus.
abstract: A controlled crossover study was performed in 8 diabetic patients with chronic portal-systemic encephalopathy. After a basal period the patients were treated during periods A and B. During period A, a meat protein diet (0.8 g/kg body wt, approximately 1800 kcal/day) was consumed and neomycin plus laxatives were given. During period B patients received vegetable protein (0.8 g/kg body wt, 1800 kcal/day). This diet was supplemented with psyllium fiber to reach 35 g of fiber per day. Four patients were randomly assigned to receive the treatments in the order A-B and the other 4 patients in the order B-A. At the end of the first experimental period, fasting glucose levels were 204 +/- 86 mg% in the meat protein diet group and 127 +/- 8 mg% in the vegetable protein diet group (p less than 0.014). The patients were receiving 2.5 +/- 0.2 g/day and 2.1 +/- 0.5 g/day of tolbutamide at the end of the meat protein diet and vegetable protein diet, respectively. In all cases, fasting glucose levels decreased at the end of the vegetable diet period regardless of the previous treatment. An improvement of greater than or equal to 25 mg% of fasting glucose levels was observed in 7 of the 8 patients after the vegetable protein diet and in no case after the meat protein diet (p less than 0.0078). The parameters of encephalopathy were comparable at the end of both the meat protein diet and the vegetable protein diet. A significant increase in the number of bowel movements was noticed after the vegetable diet plus fiber (p less than 0.01). We propose the use of vegetable diet plus fiber to facilitate the treatment of patients with both diabetes and hepatic encephalopathy.
authors.forename: M
authors.initials: M
authors.lastname: Uribe
authors.forename: M
authors.initials: M
authors.lastname: Dibildox
authors.forename: S
authors.initials: S
authors.lastname: Malpica
authors.forename: E
authors.initials: E
authors.lastname: Guillermo
authors.forename: A
authors.initials: A
authors.lastname: Villallobos
authors.forename: L
authors.initials: L
authors.lastname: Nieto
authors.forename: F
authors.initials: F
authors.lastname: Vargas
authors.forename: G
authors.initials: G
authors.lastname: Garcia Ramos
mesh_terms: D000328:Adult; D000596:Amino Acids / Q000032:analysis; D001663:Bilirubin / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000178:diet therapy*; D004043:Dietary Fiber / Q000008:administration & dosage; D004044:Dietary Proteins / Q000008:administration & dosage*; D002149:Energy Intake; D005260:Female; D005527:Food, Fortified; D005934:Glucagon / Q000097:blood; D006501:Hepatic Encephalopathy / Q000097:blood / Q000178:diet therapy*; D006801:Humans; D007328:Insulin / Q000097:blood; D008103:Liver Cirrhosis / Q000178:diet therapy; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000008:administration & dosage; D010940:Plant Proteins / Q000008:administration & dosage*; D011620:Psyllium / Q000008:administration & dosage*; D014044:Tolbutamide / Q000008:administration & dosage
chemical_list: D000596:Amino Acids; D004043:Dietary Fiber; D004044:Dietary Proteins; D007328:Insulin; D010940:Plant Proteins; D011620:Psyllium; D005934:Glucagon; D014044:Tolbutamide; D009355:Neomycin; D001663:Bilirubin